26,415 Shares in Cencora, Inc. (NYSE:COR) Bought by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 26,415 shares of the company's stock, valued at approximately $5,935,000.

Other large investors have also bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in shares of Cencora by 0.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock worth $1,990,542,000 after acquiring an additional 78,066 shares in the last quarter. Boston Partners raised its stake in shares of Cencora by 2.6% in the 4th quarter. Boston Partners now owns 5,007,100 shares of the company's stock valued at $1,128,058,000 after purchasing an additional 125,611 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Cencora by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock valued at $969,471,000 after purchasing an additional 130,213 shares in the last quarter. Invesco Ltd. boosted its position in shares of Cencora by 20.4% during the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock worth $728,757,000 after buying an additional 550,246 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Cencora by 11.6% during the fourth quarter. Northern Trust Corp now owns 2,421,237 shares of the company's stock worth $544,004,000 after buying an additional 252,028 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

COR traded up $13.23 during trading on Wednesday, hitting $304.04. The stock had a trading volume of 2,384,298 shares, compared to its average volume of 1,509,714. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a one year low of $214.77 and a one year high of $308.93. The company has a 50 day moving average price of $274.32 and a 200-day moving average price of $252.29. The firm has a market cap of $58.96 billion, a price-to-earnings ratio of 43.25, a P/E/G ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the prior year, the company posted $3.80 EPS. The company's revenue was up 10.3% compared to the same quarter last year. As a group, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. UBS Group raised their price target on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. JPMorgan Chase & Co. increased their price objective on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Finally, Evercore ISI upped their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $290.00.

Insider Transactions at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now owns 315,913 shares in the company, valued at approximately $89,027,442.53. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock worth $13,580,967 over the last three months. 10.80% of the stock is owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.